Develops drugs for rare immune-inflammatory diseases and cancer.
Jun 2026Revenue $130K/yrExpenses $12.1M/yr
No trendCash runway ≈ 1.4 years from Jun 2026
Figures by year
When will Vyome Holdings be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $130K and expenses $12.1M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $320K | $10.8M | −$10.5M |
| Dec 2024 | $257K | $1.26M | −$1.01M |
| Dec 2023 | $8.68M | $24.1M | −$15.4M |
| Dec 2022 | $11.2M | $57.6M | −$46.4M |
| Dec 2021 | $13.6M | $71.5M | −$57.9M |
| Dec 2020 | $11.3M | $23.8M | −$12.5M |
| Dec 2019 | $3.28M | $26.5M | −$23.2M |
| Dec 2018 | $9.10M | $46.1M | −$37.0M |
| Dec 2017 | $9.91M | $44.3M | −$34.4M |
| Dec 2016 | $3.39M | $22.9M | −$19.5M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.